Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Author(s): PierFranco Conte, MD, PhD^1,2; Giancarlo Bisagni, MD³; Federico Piacentini, MD, PhD⁴; Samanta Sarti, MD, PhD⁵; Santino Minichillo, MD⁶; Elisa Anselmi, MD⁷; Michele Aieta, MD⁸; Vittorio Gebbia, MD⁹; Alessio Schirone, MD¹⁰; Antonino Musolino, MD, PhD¹¹; Ornella Garrone, MD, PhD¹²; Alessandra Beano, MD¹³; Anita Rimanti, MD¹⁴; Francesco Giotta, MD¹⁵; Anna Turletti, MD¹⁶; Federica Miglietta, MD^17,18; Maria Vittoria Dieci, MD^17,18; Roberto Vicini, PhD¹⁹; Sara Balduzzi, MD²⁰; Robert D’Amico, PhD⁴; and Valentina Guarneri, MD, PhD^17,18

Source: DOI: 10.1200/JCO.23.00790 Journal of Clinical Oncology 41, no. 32 (November 10, 2023) 4976-4981.

Dr. Anjan Patel's Thoughts

This is a 10-year follow-up of the ShortHER study using nine weeks vs. 12 months of adjuvant trastuzumab in HR+ non-metastatic breast cancer. With long-term follow-up, non-inferiority could not be claimed statistically. Still, the DFS/OS results are identical in those patients with N0-N3 disease, while those with N4 disease seemed to have a significant difference favoring 12 months of therapy, suggesting that volume/burden of disease drives the margin of benefit in adjuvant trastuzumab therapy.

We present the final analysis of the phase III noninferiority, randomized ShortHER trial comparing 9 weeks versus 1 year of adjuvant trastuzumab with chemotherapy in patients with human epidermal growth factor receptor 2–positive (HER2+) early breast cancer (BC). Women with HER2+ BC were randomly assigned to anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or 9-week trastuzumab (arm B, short). Here, we report the second coprimary end point overall survival (OS), updated disease-free survival (DFS), and outcomes according to hormone receptor status, age, and nodal status. At a median follow-up of 9 years, 10-year DFS is 77% versus 78% in the long versus short arm, respectively. Ten-year OS is 89% versus 88% in the long versus short arm, respectively. 10-year DFS rates in the long versus short arm according to nodal status are N0 81% versus 85%; N1-3 77% versus 79%; and N4+ 63% versus 53%. Ten-year OS rates in long versus short arm according to nodal status are N0 89% versus 95%%; N1-3 92% versus 89%; and N4+ 84% versus 64%. The updated analysis of the ShortHER trial shows that 1-year trastuzumab is the standard treatment for patients with HER2+ early BC as noninferiority cannot be claimed. However, numerically, the differences for the patients at low or intermediate risk (N0/N1-3) is negligible, while patients with N4+ have a clear benefit with 1-year trastuzumab.

Author Affiliations

¹S Camillo Hospital, IRCCS, Venezia, Italy; ²University of Padova, Padova, Italy; ³Department of Oncology and Advanced Technologies, Azienda USL-IRCCS, Reggio Emilia, Italy; ⁴Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Modena, Italy; ⁵IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori,” IRST srl, Meldola, Italy; ⁶Medical Oncology, Bellaria Hospital, Bologna, Italy; ⁷Department of Oncology and Hematology, ASL Piacenza, Piacenza, Italy; ⁸Medical Oncology, IRCCS-CROB, Rionero in Vulture, Italy; ⁹Kore University, Enna and La Maddalena Clinic, Palermo, Italy; ¹⁰S Anna University Hospital, Ferrara, Italy; ¹¹University Hospital, Parma, Italy; ¹²IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy; ¹³Breast Oncology, Città della Salute e della Scienza, Torino, Italy; ¹⁴Carlo Poma Hospital, ASST Mantova, Mantova, Italy; ¹⁵IRCCS Istituto Oncologico Giovanni Paolo II, Bari, Italy; ¹⁶Senology, Ospedale Martini, ASL Città di Torino, Torino, Italy; ¹⁷Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; ¹⁸Oncology 2, Veneto Oncology Institute, IOV-IRCCS, Padova, Italy; ¹⁹Statistical Unit, University Hospital, Modena, Italy; ²⁰University of Modena and Reggio Emilia, Modena, Italy

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Findings from the PACE study show that the addition of Palbociclib to Fulvestrant was not better than Fulvestrant alone, and the addition of Avelumab to Fulvestrant improved and nearly doubled the PFS. This is compelling and should be studied further for our patients with HR+ HER2- MBC.

Ribociclib plus Endocrine Therapy in Early Breast Cancer

For your stage II – III HR+, HER2-neg breast cancer patients. Adjuvant Ribociclib + AI showed a ~3% invasive DFS benefit vs. an AI alone (90 vs 87%). This is a 3-year treatment protocol as opposed to 5 years of an AI, which some patients may appreciate.

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

This is a study showing tumor agnostic activity of trastuzumab deruxtecan (T-DXd) with an all-comer overall response rate (ORR) of 37.1%, duration of response (DOR) of 11.3 months and an overall survival (OS) of 13.4 months in an otherwise heavily pre-treated group. Those with IHC-3+ derived larger benefit than 2+. Patients with ERBB2 mutations who had no expression of HER2 were excluded from the trial.

Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study

There have been studies showing decreased recurrence in women who underwent curative breast surgeries (walking and yoga). This study assesses if it will affect the intensity of chemotherapy delivered. Although it did not affect it, women who underwent the program had better pathologic complete response (pCR), we need more studies to assess role of nutrition and exercise in treating cancer as we develop a wholesome approach to treat our patients, something we may be able to do in our practice.

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

This is another option for HR positive patients after failing hormonal therapy, with an acceptable toxicity profile. Patients were HER-2 negative. (The study does not indicate if patients were HER-2 low.) It will be interesting to see how this will fair in this population now that there is another option with Enhrtu. Interesting though, patients without visceral metastases did better with chemotherapy.

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial

Dr. Anjan Patel's Thoughts

Author Affiliations

Leave a Comment Cancel Reply

Related Articles

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

Ribociclib plus Endocrine Therapy in Early Breast Cancer

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Menu

About This Site